业务新闻

GEA supplies separator plant for trials, upscaling and production of a possible future corona vaccine to China

30 Apr 2020

In the battle against the Covid-19 virus, technology leader GEA announces an order to supply a separator plant for vaccines to China. The plant will be used for clinical samples and later for the actual production process for the manufacture of a possible future corona vaccine.

GEA centrifuge package with fully automatic SIP

GEA centrifuge package with fully automatic SIP: Steam-sterilizable and completely sealed, designed for maximum biosafety and containment. (Photo: GEA)

As the technology leader for steam-sterilizable separators in pharmaceutical production, GEA is making an important contribution to the fight against the corona virus Sars-CoV-2 with its technology and competence in the field of separators.

Steam sterilizable and designed to the highest hygienic standards

The GEA pharma skid unit ensures the so important biocontainment to prevent cross-contamination. A hermetically closed plant concept prevents the product from coming into contact with the environment. The separator system achieves maximum yield due to its gentle product treatment and high separation efficiency. The separator system is supplied in steam-sterilizable design (SIP at 2.5 bar/137°C) to ensure aseptic processing of pharmaceutical products. These systems also have the function of fully automatic on-site cleaning (CIP, "Clean-in-Place") in hygienic, highly polished design. The hydrohermetic inlet system for shear-sensitive products is patented by GEA. The plant is driven by a 3-phase alternating current motor. All parts in contact with the product are made of high-alloy stainless steels. The seals comply with FDA and USP Class VI requirements.

GEA: Solutions for vaccine production

The challenge in vaccine production is the competence to translate the findings and results of laboratory research into large-scale industrial production in such a way that they fully meet the complex requirements of biotechnological processes. Together with customers, GEA develops processes that not only allow upscaling from laboratory scale to production scale, but also ensure that the quality, safety and efficacy of each individual batch of vaccine can be checked and reproduced at any time.

GEA is a partner for practically all major global vaccine manufacturers. Separation technology using separators is one of the key technologies in vaccine production.

GEA also offers complete systems and process lines for vaccine production.

Media Relations

GEA Group Aktiengesellschaft

Peter-Müller-Str. 12


40468

Düsseldorf


Germany

+49 211 9136-0

About GEA

GEA 是食品加工行业及众多工业领域的领先供应商之一,2019 年的销售总额约达 49 亿欧元。

作为国际技术集团,我们专注于机械制造,生产运营,工艺技术及其设备组件。 GEA 为各种终端用户市场的复杂生产流程提供可持续的能源解决方案,并提供全面的服务组合。集团在长期持续增长的食品和饮料行业的收入约占其总收入的 70%。截至 2018 年 12 月 31 日,集团的全球员工已超过 18,500 人。GEA 在其业务领域中是市场和技术领导者。GEA 是德国 MDAX 上市公司(G1A,WKN 660 200),拥有 STOXX® Europe 600 指数和优选的 MSCI 全球可持续发展指数。
接收 GEA 新闻

订阅 GEA 的新闻,掌握 GEA 的创新信息和故事。

联系我们

我们随时为您提供帮助!您只需提供少量详细信息,我们就能回复您的查询。